MYCN and neuroblastoma: As we had previously found that MYCN drives immunosuppression in different tumors and that BGA002 was able to restore immune-response in MYCN-related NB, the MYCN silencing in SCLC by BGA002 opens the way to new immunotherapeutic approaches for the SCLC-N subtype as well, which is thus far resistant to immunotherapy.